In order to evaluate the usefulness of 18-fluorodeoxyglucose (FDG) positron emission
tomography (PET) in the assessment of therapeutic effects, a study was performed before …

Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis
and staging of lung cancer, but is also appealing for assessment of prognosis and treatment …

PURPOSE: To prospectively study the impact of 18F fluorodeoxyglucose (FDG) positron
emission tomography (PET) on clinical management of patients with non–small-cell lung …

Background: To analyse current literature on FDG-PET for evaluation of lung lesions, N-
staging, M-staging, and recurrence of lung cancer for the third German Consensus …

BACKGROUND: Follow-up of patients treated with curative intent for non-small cell lung
cancer (NSCLC) with X-ray or CT-scans is of unproven value. Furthermore, most patients …

Since its introduction in 1974, positron emission tomography (PET) has gained widespread
use, especially in diagnosis and staging of lung cancer. In this respect, 18F …

The aim of this study was to determine whether quantitative information obtained from [18 F]
fluorodeoxyglucose positron emission tomography (18 F-FDG PET) has a prognostic …

Objectives: F18-fluorodeoxyglucose positron emission tomography-computed tomography
(FDG-PET/CT), which allows differentiation between malignant and benign lesions based on …

BACKGROUND A fundamental property of malignant tumors is increased glucose
metabolism, which can be estimated by imaging the glucose analog fluorodeoxyglucose …

Study objective To evaluate the accuracy of positron emission tomography (PET) in
determining the presence of malignancy in patients presenting with new lung findings, either …